Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 10c, Lowers FY EPS Guidance
Amneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.04, $0.10 worse than the analyst estimate of $0.14. Revenue for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)